Open AccessA novel m6A‐related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients
Author(s) -
Xie Shiyang,
Wang Yaxuan,
Huang Jin,
Li Guang
Publication year - 2022
Publication title -
iet systems biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.367
H-Index - 50
eISSN - 1751-8857
pISSN - 1751-8849
DOI - 10.1049/syb2.12036
Subject(s) - hepatocellular carcinoma , proportional hazards model , biology , gene , gene signature , survival analysis , oncology , liver cancer , gene expression , medicine , cancer research , genetics
Liver hepatocellular carcinoma (LIHC) comprises most cases of liver cancer with a poor prognosis. N 6 ‐methyladenosine (m6A) plays important biological functions in cancers. Thus, the present research was aimed to determine biomarkers of m6A regulators that could effectively predict the prognosis of LIHC patients. Based on the data collected from the Cancer Genome Atlas (TCGA) database, the correlation between the mRNA expression levels and copy number variation (CNV) patterns were determined. Higher mRNA expression resulted from the increasing number of 9 genes. Using the univariate Cox regression analysis, 11 m6A regulators that had close correlations with the LIHC prognosis were identified. In addition, under the support of the multivariate Cox regression models and the least absolute shrinkage and selection operator, a 4‐gene (YTHDF2, IGF2BP3, KIAA1429, and ALKBH5) signature of m6A regulators was constructed. This signature was expected to present a prognostic value in LIHC (log‐rank test p value < 0.0001). The GSE76427 ( n = 94) and ICGC‐LIRI‐JP ( n = 212) datasets were used to validate the prognostic signature, suggesting strong power to predict patients' prognosis for LIHC. To sum up, genetic alterations in m6A regulatory genes were identified as reliable and effective biomarkers for predicting the prognosis of LIHC patients.